Drug Discovery

#Assay development & optimisation #Drug discovery #In vitro

Eurofins, a focus on drug discovery expertise

Eurofins Discovery is a CRO with a range of expertise in drug discovery. Christina Shasserre, Senior VP spoke to Lu Rahman about some of the company’s current COVID-related work as well as offering insight into the drug discovery landscape.   LR: Are you able to share some of Eurofins Discovery’s… Read More

#News #Opinion

#AI / data analytics / healthtech / informatics #Drug discovery

Precision medicine in the era of artificial intelligence

Dr Lotfi Chouchane and Dr. Javaid Sheikh, Weill Cornell Medicine-Qatar, outline the challenges and opportunities ahead for drug discovery Precision medicine is an emerging model for the next generation of clinical care that will capitalise on the dynamic interaction between individual biology, lifestyle, behaviour, and environment. It holds huge promise… Read More

#Exclusive Content #News #Trends & Analysis

#Drug discovery #Flow Cytometry

Why flow cytometry in drug discovery is a real life-saver

Capable of boasting high-throughput, accurate, multiparameter and highly reproducible results, Urmi Roy, Global Product Manager Miltenyi Biotec outlines the benefits of flow cytometry offering case study examples for its use. Increasing numbers of drug discovery programmes are targeting cellular mechanism and phenotype as a promising avenue for new therapies. The… Read More

#Exclusive Content #News

#Drug development #Drug discovery #Drug targets

Genetic modifiers: Why drug developers should care

Sebastian Nijman, Chief Scientific Officer, Scenic Biotech, explains why harnessing genetic modifiers holds great potential to address the present drug target vacuum and why every drug developer should care about them. According to the National Institute of Health (NIH), approximately 500 of the many thousands of human diseases have an approved… Read More

#Exclusive Content #News

#Assay development & optimisation #Drug discovery

Accelerating assay development optimisation for drug discovery

Dr. Zack Gurard-Levin, Chief Scientific Officer, SAMDI Tech offers five challenges and solutions for optimal assay development in drug discovery Developing a suitable assay is critical to identifying and characterising novel drug leads. While designing an assay may appear straightforward, developing the assay in an optimised format for a particular… Read More

#Exclusive Content

#Drug discovery

Metrion Biosciences and LifeArc extend drug discovery collaboration

Metrion Biosciences, a specialist ion channel CRO and drug discovery company, and LifeArc, an independent medical research charity, have announced a 12-month extension of their neuroscience drug discovery collaboration, as a result of the continued success of their ongoing agreement. The collaboration is focused on the discovery of novel selective… Read More

#Editor's Choice #News

#Clinical trials #Covid-19 #Drug development

ICON supports Pfizer and BioNTech on the investigational COVID-19 vaccine trial

ICON, provider of outsourced drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries and government and public health organisations, has announced it provided clinical trial services to the Pfizer and BioNTech investigational COVID-19 vaccine programme. Pfizer and BioNTech announced positive efficacy results from a… Read More

#Covid-19 #News

#Drug discovery

Drug discovery collaboration in neurological diseases

Servier, a global pharmaceutical group and X-Chem, a privately held drug discovery company have teamed up to identify and develop novel small molecules for the treatment of neurological disorders. Under the terms of the multi-target agreement, X-Chem will use its DNA-Encoded library (DEL) platform to identify novel small molecule leads… Read More

#News

#Drug discovery

CN Bio’s PhysioMimix technology receives FDA recognition

CN Bio, developer of single and multi organ-on-chip microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, has published co-authored research with the US Food and Drug Administration (FDA)1.The first co-published, peer-reviewed research paper between a commercial MPS provider and a regulator, demonstrates that data derived using… Read More

#Editor's Choice #News

#Drug discovery #Exhibition

SLAS2021 Digital: expertise and innovation showcase

SLAS2021 Digital will take place on 25-27 January. This year’s event promises expertise and innovation from the life sciences discovery and technology sectors. The event welcomes scientists, engineers, academics, graduate students, post-doctorates and business leaders from academia, government and industry who want to immerse themselves in the latest innovation for discovery,… Read More

#Editor's Choice #News

#Drug discovery

Five reasons why Australia holds opportunity for drug discovery projects

Colin La Galia, Epichem CEO, explains why Australia is one of international science’s ‘best kept secrets’. In an uncertain domestic environment, many drug discovery companies are looking to find safe, reliable locations to continue their important work in chemical and pharmaceutical development. There are several compelling reasons companies should consider… Read More

#News

#AI / data analytics / healthtech / informatics #Drug development #Drug discovery #Therapeutics

Boehringer Ingelheim and Google in R&D partnership

Boehringer Ingelheim has entered a collaborative agreement with Google Quantum AI (Google), focusing on researching and implementing cutting-edge use cases for quantum computing in pharmaceutical research and development (R&D), specifically including molecular dynamics simulations. The new partnership combines Boehringer Ingelheim’s leading expertise in the field of computer-aided drug design and… Read More

#Editor's Choice #News

#Drug development #Drug discovery #Life sciences #Narrated podcasts

2030 Life Sciences and Health in the Digital Age (Part 2)

The Pistoia Alliance has developed a research paper which sets out to consider what the life science, biopharma R&D and healthcare ecosystem might look like in 2030, in particular how the increasing adoption and sophistication of technology will affect companies and patients alike. This article is the second part of… Read More

#Podcasts

#AI / data analytics / healthtech / informatics #Biologics #Drug discovery #Pharmaceuticals

Is the pharmaceutical industry ready to listen directly to patients?

Dr Elizabeth Fairley, COO and co-founder of social intelligence company Talking Medicines, explains how technology has shaped the drug landscape and why actually listening to patients might be the breakthrough the industry needs. There are more drugs on the market today than ever before and the drug pipeline is massively… Read More

#Editor's Choice #News #Opinion